Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.48 |
| ▸ | PDE4A | P27815 | 11/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145065 | 0.93 | PDE4A (0.51) | PDE5APDE1APDE1BPDE1CPDE4D | |
| Hydrochloric Acid SCHEMBL7646226 | 0.93 | PDE4D (0.50) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6605978 | 0.92 | PDE5A (0.51) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6603434 | 0.92 | LMNA (0.50) | PDE4BTSHRSMN1; SMN2ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL147488 | 0.92 | LMNA (0.49) | PDE4BTSHRSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL6601657 | 0.91 | RAB9A (0.47) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6602086 | 0.89 | PDE5A (0.49) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6602147 | 0.89 | PDE5A (0.46) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6584543 | 0.89 | PDE5A (0.52) | PDE5APDE1APDE1BPDE1CPDE4D | |
| SCHEMBL6602063 | 0.88 | PDE4B (0.52) | PDE5APDE1APDE1BPDE1CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | claimed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | MERK PANTENT GMBH (DE) | 2005-03-31 | — | — | US | disclosed |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1463509-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GmbH (DE) | 2004-10-06 | — | — | EP | disclosed |
| EP-0922036-B1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GMBH (DE) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003037349-A1 | TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2003-05-08 | — | — | WO | disclosed |
| US-6479494-B1 | THEY INHIBIT SELECTIVELY PHOSPHODIESTERASE IV, WHICH CAUSES AN INCREASE OF THE INTRACELLULAR CAMP LEVEL AS CAMP INHIBITS BONE DECREASING CELLS AND STIMULATES BONE INCREASING CELLS FOR TREATMENT OF OSTEOPOROSIS | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6107295-A | Arylalkanoyl pyridazines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-22 | — | — | US | disclosed |
| EP-0922036-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GmbH (DE) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006704-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | PDE5A 2251/4885PDE1A 907/4885PDE1B 810/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | PDE5A 2251/4885PDE1A 907/4885PDE1B 810/4885 |
| US-20050070529-A1 | Use of type 4 phosphodiesterase inhibitors in myocardial diseases | PDE4A, PDE4B, PDE12 | PDE5A 7/4885PDE1A 19/4885PDE1B 21/4885 |
| US-20040259863-A1 | Type 4 phosphodiesterase inhibitors and uses thereof | PDE4A, PDE4B, PDE4C | PDE5A 7/4885PDE1A 20/4885PDE1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.